Amoxicillin/Omeprazole/Rifabutin

阿莫西林/奥美拉唑/利福布汀

Report date: 2026/05/11 20:01:57
QIDP

Base Information

Drug NameAmoxicillin/Omeprazole/Rifabutin
Drug Alias Name阿莫西林/利福布汀/奥美拉唑Omeprazole/amoxicillin/rifabutin利福布汀/阿莫西林/奥美拉唑Rifabutin/amoxicillin/omeprazole奥美拉唑镁/阿莫西林/利福布汀 +[10] 
ClassificationNatural product/ExtractSmall molecules > Heterocyclic drugs > Antibiotics > β-lactam antibiotics
Mechanisms of ActionProton pump inhibitorsBacterial DNA-directed RNA polymerase inhibitorsBacterial penicillin-binding protein inhibitors
TargetsProton pumpBacterial DNA-directed RNA polymeraseBacterial penicillin-binding protein
Therapy Area/IndicationsHelicobacter pylori infectionDyspepsia
Global Approved IndicationsHelicobacter pylori infection
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2019/11/01
Country/TerritoryUnited StatesMainland China
CombinationsYes AmoxicillinRifabutinOmeprazole
Global Highest StatusApproved
Highest Status in ChinaIND
Originator CompaniesRedhill Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesTalicia Holdings IncGaelan Medical Trade LLCKukbo Co Ltd +[4] 
Inactive CompaniesRedhill Biopharma Ltd
Active IndicationsHelicobacter pylori infection
Inactive IndicationsDyspepsia

Other Information

ATC CodeA02BD
Related LinksN/A